Insilico Medicine, Biopharmaceuticals Strike: AI Drug Deal Heads Toward $2.5B
Insilico Medicine and SK Biopharmaceuticals unveiled a milestone collaboration worth up to $2.5 billion to develop ne...
Which Aristocrat ETF Minimizes Taxes In Retirement compares options to help you minimize tax drag in retirement.
22,003 articlesInsilico Medicine and SK Biopharmaceuticals unveiled a milestone collaboration worth up to $2.5 billion to develop ne...
The U.S. economy posted 2.2% growth for 2025, a modest slowdown from 2024, with late-year softness in Q4. Consumers a...
AbbVie’s Apogee deal has revived takeover chatter. Three Nasdaq-listed biotech players are emerging as plausible biot...
The Supreme Court ruled tariffs illegal, removing a key policy tool and shaking markets. Bitcoin price reacts supreme...
Investors are moving past SpaceX hype toward proven AI cash generators. This report explains why NVIDIA stands out as...
Bitcoin has seen shifts in on-chain dynamics that suggest selling pressure may be easing. Yet large holders continue ...
A high-profile premiere moment sparked online discussion and financial lessons. This article breaks down how fame, pu...
When a public fundraiser surfaces after a family tragedy, questions follow. This article breaks down the ethics, the ...
A leading market strategist argues the AI-led pullback is routine profit-taking after a rapid rally, with the AI infr...
The AI era has reshaped Palantir's role in enterprise data. This guide weighs the buy, sell, hold case for 2026 with ...
JB Straubel’s initial pitch to Elon Musk missed the mark on aviation, but his pivot to electric cars launched Tesla t...
A major fund slashed its stake in Papa John's, triggering questions about the stock's outlook. This guide explains wh...